NEULANDLAB
Neuland Laboratories Limited
Each stock's 10,000-path forecast, rendered as light.
Neuland Laboratories Limited (NEULANDLAB) Stock Analysis & Case Study
Is NEULANDLAB a good buy? The data-driven verdict.
Neuland Laboratories Limited (NEULANDLAB) trades at ₹22,855,on the numbers it mixed signals, a Downstox Snapshot Score of 47/100.
On the numbers, Neuland Laboratories Limited (NEULANDLAB) mixed signals, a Downstox Snapshot Score of 47/100, weighing expensive at 58.9× earnings, ROE of 21.2%, a 51% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
NEULANDLAB fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How NEULANDLAB ranks against the 2,373 companies in our screener
- NEULANDLAB's market cap of 29,323 Cr ranks in the 88th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NEULANDLAB's book value of ₹1,461 ranks in the top 2% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NEULANDLAB's promoter holding of 32.6% ranks in the 10th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NEULANDLAB's 3-year profit (PAT) growth of 30.0% ranks in the 69th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NEULANDLAB's 3-year revenue growth of 19.0% ranks in the 72nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NEULANDLAB's debt-to-equity ratio of 0.16x is lower than 68% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is NEULANDLAB overvalued? NEULANDLAB P/E vs peers
NEULANDLAB trades at 58.9× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
NEULANDLAB share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of NEULANDLAB history (33%/yr drift, 50%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| NEULANDLAB 2027 | ₹12,505 | ₹23,313 | ₹43,462 | +2% |
| NEULANDLAB 2028 | ₹9,671 | ₹23,779 | ₹58,469 | +4% |
| NEULANDLAB 2029 | ₹7,926 | ₹24,255 | ₹74,222 | +6% |
| NEULANDLAB 2030 | ₹6,937 | ₹24,741 | ₹88,241 | +8% |
| NEULANDLAB 2031 | ₹6,066 | ₹25,236 | ₹1,04,989 | +10% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability NEULANDLAB goes up, or doubles?
The bull case for NEULANDLAB
- NEULANDLAB's return on equity of 21.2% ranks in the 86th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NEULANDLAB's return on capital employed of 26.5% ranks in the 89th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹74,222.
The bear case & risks
- NEULANDLAB's P/E of 58.9x is lower than 22% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 15.6× price-to-book means most of the value is intangible/expectations, not assets on the books.
- High historical volatility (50%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹7,926.
NEULANDLAB volatility & expected range, how bumpy is the ride?
Over the last 9.8 years NEULANDLAB compounded at 33%/year with annualized volatility of 50%. That volatility implies a 1-year 80% range of ₹12,505-₹43,462, the honest backbone behind any single price target.
NEULANDLAB price forecast, the full 60-month probability fan
NEULANDLAB price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds NEULANDLAB hits common targets within the simulated horizon?
Full multi-horizon detail on the NEULANDLAB price target & forecast page.
NEULANDLAB Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. NEULANDLAB scores 6/8, mixed financial health.
NEULANDLAB MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy NEULANDLAB with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.75% | 2.8× |
| Zerodha | 35.93% | 2.8× |
| Groww | 35.75% | 2.8× |
| Dhan | 35.93% | 2.8× |
| Kotak Neo | 35.97% | 2.8× |
| Paytm Money | 35.75% | 2.8× |
| Pocketful | 35.66% | 2.8× |
| Fyers | 35.71% | 2.8× |
| Anand Rathi | 35.93% | 2.8× |
| Bajaj Broking | 40.00% | 2.5× |
| Share IndiaCHEAPEST | 35.42% | 2.8× |
Compare every broker on the NEULANDLAB MTF page.
Which ace investors hold NEULANDLAB?
Held by 1 tracked superstar investor (from public NSE/BSE disclosures):
About Neuland Laboratories Limited: sector, index & market-cap context
Neuland Laboratories Limited (NEULANDLAB) is a mid-cap NSE-listed company, and a constituent of the Nifty 500 index, with a market capitalisation of ₹29,323 Cr. See more stocks on our screener.
How the NEULANDLAB Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Neuland Laboratories Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
NEULANDLAB analysis, FAQs
Is Neuland Laboratories Limited (NEULANDLAB) a good buy?
On the numbers, Neuland Laboratories Limited (NEULANDLAB) mixed signals, a Downstox Snapshot Score of 47/100, weighing expensive at 58.9× earnings, ROE of 21.2%, a 51% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is NEULANDLAB overvalued or undervalued?
NEULANDLAB trades at 58.9× earnings, expensive versus the ~22× long-run Nifty average.
What is the NEULANDLAB share price target for 2031?
NEULANDLAB's probability-weighted 2031 median target is ₹25,236, with an 80% range of ₹6,066-₹1,04,989 (10,000-path Monte-Carlo).
What is the probability NEULANDLAB doubles in 5 years?
The modelled probability of NEULANDLAB reaching ₹45,710 (2×) within 5 years is 30%.
What is the bull case for NEULANDLAB?
NEULANDLAB's return on equity of 21.2% ranks in the 86th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. NEULANDLAB's return on capital employed of 26.5% ranks in the 89th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in NEULANDLAB?
NEULANDLAB's P/E of 58.9x is lower than 22% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 15.6× price-to-book means most of the value is intangible/expectations, not assets on the books. High historical volatility (50%/yr) means a wide, bumpy range of outcomes, size positions accordingly.